Home › Funds › Sofinnova Investments, Inc. › NKTR

Sofinnova Investments, Inc. position in NKTR

NEKTAR THERAPEUTICS · Health Care

Sofinnova Investments, Inc. reported holding 471,763 shares of NKTR (NEKTAR THERAPEUTICS) in its Q2 2026 13F filing — a position valued at US$32.9M, representing 1.75% of its reported portfolio and ranking #21 among its reported holdings. Sofinnova Investments, Inc. has disclosed NKTR holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

Latest position (Q2 2026)471.76K sh
Reported value held$32.93M
Portfolio Weight1.75%
First reportedQ3 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Sofinnova Investments, Inc.'s NKTR position evolved

Sofinnova Investments, Inc. first disclosed a stake in NKTR in Q3 2025 at 118,419 shares (US$6.7M). The position peaked in Q1 2026 at 509,546 shares, worth US$36.7M. Across 4 filings, Sofinnova Investments, Inc. increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 471,763 shares valued at US$32.9M — a reduction of -37,783 shares quarter over quarter.. Notable position changes include a 270% increase in Q4 2025 (shares rose 70% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2025 118.42K $6.74M New
Q4 2025 438.63K $18.55M Add
Q1 2026 509.55K $36.66M Add
Q2 2026 471.76K $32.93M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NKTR and 13F data

NKTR (NEKTAR THERAPEUTICS) is a Health Care company. 70 other funds we track also report a position in NKTR — the largest reported positions include Two Seas Capital LP (US$202.6M), BVF INC/IL (US$166.9M), Vestal Point Capital, LP (US$69.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NKTR

All NKTR fund holders →

FAQ

How long has Sofinnova Investments, Inc. held NKTR?

Sofinnova Investments, Inc. has disclosed NKTR holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

What is Sofinnova Investments, Inc.'s current position in NKTR?

As of Q2 2026, Sofinnova Investments, Inc. holds 471.76K shares of NKTR (NEKTAR THERAPEUTICS), valued at $32.93M, representing 1.75% of its reported portfolio and ranking #21.

Has Sofinnova Investments, Inc. been buying or selling NKTR?

In the latest 13F filing (Q2 2026), Sofinnova Investments, Inc. reduced its position in NKTR. The position peaked in Q1 2026 at 509.55K shares.

Which other funds hold NKTR?

Other major institutional holders of NKTR include Two Seas Capital LP, BVF INC/IL, Vestal Point Capital, LP, among 70 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.